The MIRASOL trial, a pivotal Phase III randomized controlled trial, is currently evaluating the efficacy and safety of MIRV in patients with FRα‐positive platinum‐resistant ovarian cancer. This evidence concerns the gene FOLR1 and ovarian carcinoma.